MedMira Inc.

123 articles about MedMira Inc.

• Progress Update on Securities

  8/30/2023

  MedMira Inc. has completed, with its Transfer Agent, the process and has received confirmation by the TSX.v as follows:.

• MedMira Reports Third Quarter Results FY2023

  6/29/2023

  MedMira Inc., reported on its financial results for the quarter ended April 30, 2023.

• MedMira Reports Second Quarter Results FY2023

  4/3/2023

  MedMira Inc., reported on its financial results for the quarter ended January 31, 2023.

• Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada

  3/14/2023

  MedMira Inc. provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP antibody test.

• MedMira Enters into Partnership with Maternova for USA and Latin America

  2/20/2023

  MedMira Inc. announces the singing of a multinational distribution agreement with ​Maternova, Inc., Rhode Island, USA.

• MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

  1/11/2023

  Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA CoV2Flu Antigen Test.

• Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

  1/3/2023

  MedMira Inc. announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection -, in the special edition of Pathogens by MDPI, a Swiss based medical journal.

• MedMira Reports First Quarter Results FY2023

  12/30/2022

  MedMira Inc., reported on its financial results for the quarter ended October 31, 2022.

• MedMira Introduces VYRA TriDemic

  12/29/2022

  MedMira Inc. presents its latest addition to the VYRATM product line, the VYRATM TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus.

• MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

  10/14/2022

  MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.

• MedMira Strengthens and Expands Board

  7/14/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas Bergmann was appointed as the Company’s independent Chairman.

• MedMira Reports Third Quarter Results FY2022

  6/29/2022

  MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022.

• MedMira Receives Patent for its Unique Quantitative Diagnostic System

  6/6/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.

• MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

  5/27/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.

• MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

  5/12/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP).

• MedMira Reports Second Quarter Results FY2022

  4/1/2022

  MedMira Inc., reported on its financial results for the quarter ended January 31, 2022.

• MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

  3/9/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada.

• MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

  2/9/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test.

• MedMira Provides a Pre-Annual General Meeting Update

  2/4/2022

  Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development progress.

• MedMira Reports First Quarter Results FY2022

  12/31/2021

  MedMira Inc., reported on its financial results for the quarter ended October 31, 2021.